{"description":"This was a web-based multiple choice questionnaire survey of pharmacists which did not include safety information as adverse events were not planned to be collected in this study. Data '0' for total number of participants at risk/affected for sections all-cause mortality, serious adverse events, and other (not including serious adverse events) signifies that adverse events were not collected and assessed in this study.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":0,"description":"Pharmacists included in Nikkei Medical Online Panel, active in clinical practice, and with valid contact details who belonged to hospitals and have instructed the dosing of NINLARO (ixazomib) in combination with lenalidomide and dexamethasone (IRD therapy) to patients were selected to participate in the survey.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Pharmacists in Hospitals Prescribing NINLARO"}],"frequencyThreshold":"0","timeFrame":"All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events data were not collected/assessed in this study"}